Priyabrata Mukherjee, PhD

Priyabrata Mukherjee

The University of Oklahoma Health Sciences Center
975 NE 10th ST, BRC 1409A
Oklahoma City, OK 73104 

PHONE: (405) 271-1133

Fax: (405) 271-2141

E-MAIL: Priyabrata-Mukherjee@ouhsc.edu

TITLES

Professor, Department of Pathology, Experimental Pathology

Peggy and Charles Stephenson Endowed Chair in Cancer Laboratory Research, College of Medicine and Stephenson Cancer Center

EDUCATION

University of Burdwan
India
BS, Chemistry, 1992

University of Burdwan
India
MS, Chemistry, 1994

University of Poona
India
PhD, Chemistry, 2000

Council of Scientific Industrial Research
India
Junior Research Fellow, 1996

Council of Scientific Industrial Research
India
Senior Research Fellow, 2000

Texas Christian University
Fort Worth, TX
Postdoctoral Fellow, 2004

Harvard Medical School/Children's Hospital
Boston, MA
Research Fellow, 2004

Mayo Clinic
Rochester, MN
Senior Research Fellow, 2005

Research Interests/Sub-Specialty

  • Programming tumor microenvironment by nanoparticles
  • Anti-Angiogenic property of inorganic nanoparticles
  • Metabolic enzyme and angiogenesis
  • Identification of new molecular targets using nanotechnology
  • Nanoendocytosis
  • Understanding cellular processes using engineered nanoparticles
  • Metabolic enzymes in cancer

PUBLICATIONS

Click link for abstract

  1. Bhattacharyya S, Bhattacharya R, Curley S, McNiven MA, Mukherjee P. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14541-6. doi: 10.1073/pnas.1006507107. Epub 2010 Aug 2.
  2. Bhattacharyya S, Khan S, Curran G, Robertson JD, Bhattacharya R, Mukerjee P. Efficient delivery of gold nanoparticles by dual receptor targeting. Angew Chem. 2011 Nov 16;23(43):5034-5038. DOI: 10.1002/adma.201102287.
  3. Arvizo RR, Saha S, Wang E, Robertson JD, Bhattacharya R, Mukherjee P. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6700-5. doi: 10.1073/pnas.1214547110. Epub 2013 Apr 8.
  4. Saha S, Xiong X, Chakraborty PK, Shameer K, Arvizo RR, Kudgus RA, Dwivedi SK, Hossen MN, Gillies EM, Robertson JD2, Dudley JT1, Urrutia RA, Postier RG, Bhattacharya R, Mukherjee P. Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano. 2016 Dec 27;10(12):10636-10651. doi: 10.1021/acsnano.6b02231. Epub 2016 Oct 19.
  5. Dey A1, Mustafi SB, Saha S, Kumar Dhar Dwivedi S, Mukherjee P, Bhattacharya R,. Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy. 2016;12(4):659-70. doi: 10.1080/15548627.2016.1147670.
  6. Banerjee Mustafi S, Chakraborty PK, Naz S, Dwivedi SK, Street M, Basak R, Yang D, Ding K, Mukherjee P, Bhattacharya R. MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochim Biophys Acta. 2016 Aug;1859(8):983-93. doi: 10.1016/j.bbagrm.2016.06.002. Epub 2016 Jun 22.
  7. Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22;7(12):15093-104. doi: 10.18632/oncotarget.7618.
  8. Ha JH, Yan M, Gomathinayagam R, Jayaraman M, Husain S, Liu J, Mukherjee P, Reddy EP, Song YS, Dhanasekaran DN. Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget. 2016 Nov 8;7(45):72845-72859. doi: 10.18632/oncotarget.12069.
  9. Banerjee Mustafi S, Chakraborty PK, Dwivedi SK, Ding K, Moxley KM, Mukherjee P, Bhattacharya R. BMI1, a new target of CK2α. Mol Cancer. 2017 Mar 7;16(1):56. doi: 10.1186/s12943-017-0617-8.
  10. Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M, Mannel R, Moore K, McMeekin S, Yang D, Zuna R, Ding K, Tsiokas L, Bhattacharya R, Mukherjee P. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 May 22;8:14634. doi: 10.1038/ncomms14634.